Tìm theo
Indinavir
Các tên gọi khác (2) :
  • (1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-pentonamide
  • Indinavir
Thuốc trị ký sinh trùng, chống nhiễm khuẩn
Thuốc Gốc
Small Molecule
CAS: 150378-17-9
ATC: J05AE02
ĐG : Apotheca Inc.
CTHH: C36H47N5O4
PTK: 613.7895
A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem]
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
Phân tử khối
613.7895
Monoisotopic mass
613.362805017
InChI
InChI=1S/C36H47N5O4/c1-36(2,3)39-35(45)31-24-40(22-26-12-9-15-37-21-26)16-17-41(31)23-29(42)19-28(18-25-10-5-4-6-11-25)34(44)38-33-30-14-8-7-13-27(30)20-32(33)43/h4-15,21,28-29,31-33,42-43H,16-20,22-24H2,1-3H3,(H,38,44)(H,39,45)/t28-,29+,31+,32-,33+/m1/s1
InChI Key
InChIKey=CBVCZFGXHXORBI-PXQQMZJSSA-N
IUPAC Name
(2S)-1-[(2S,4R)-4-benzyl-2-hydroxy-4-{[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]carbamoyl}butyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide
Traditional IUPAC Name
indinavir
SMILES
CC(C)(C)NC(=O)[[email protected]@H]1CN(CC2=CN=CC=C2)CCN1C[[email protected]@H](O)C[[email protected]@H](CC1=CC=CC=C1)C(=O)N[[email protected]@H]1[[email protected]](O)CC2=CC=CC=C12
Độ tan chảy
167.5-168 °C
Độ hòa tan
0.015 mg/ml
logP
2.9
logS
-4.1
pKa (strongest acidic)
13.19
pKa (Strongest Basic)
7.37
PSA
118.03 Å2
Refractivity
175.89 m3·mol-1
Polarizability
68.63 Å3
Rotatable Bond Count
12
H Bond Acceptor Count
7
H Bond Donor Count
4
Physiological Charge
1
Number of Rings
5
Bioavailability
0
MDDR-Like Rule
true
Dược Lực Học : Indinavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Indinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.
Cơ Chế Tác Dụng : A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem] Indinavir inhibits the HIV viral protease enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.
Dược Động Học :
▧ Absorption :
Rapidly absorbed
▧ Protein binding :
60%
▧ Metabolism :
Hepatic. Seven metabolites have been identified, one glucuronide conjugate and six oxidative metabolites. In vitro studies indicate that cytochrome P-450 3A4 (CYP3A4) is the major enzyme responsible for formation of the oxidative metabolites.
▧ Route of Elimination :
Less than 20% of indinavir is excreted unchanged in the urine.
▧ Half Life :
1.8 (± 0.4) hours
Độc Tính : Symptoms of overdose include myocardial infarction and angina pectoris.
Chỉ Định : Indinavir is an antiretroviral drug for the treatment of HIV infection.
Tương Tác Thuốc :
  • Abacavir The serum concentration of Abacavir may be decreased by protease inhibitors such as Indinavir. The antiviral response should be closely monitored.
  • Abiraterone Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely.
  • Acenocoumarol The protease inhibitor, indinavir, may increase the anticoagulant effect of acenocoumarol.
  • Alprazolam The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, alprazolam.
  • Aluminium The antacid decreases the absorption of indinavir
  • Amiodarone Indinavir increases the effect and toxicity of amiodarone
  • Anisindione The protease inhibitor, indinavir, may increase the anticoagulant effect of anisindione.
  • Astemizole Increased risk of cardiotoxicity and arrhythmias
  • Atazanavir Increased risk of hyperbilirubinemia with this association
  • Atorvastatin Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of atorvastatin by decreasing its metabolism. Concomitant therapy is contraindicated.
  • Bromazepam Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if indinavir is initiated, discontinued or dose changed. Dosage adjustments may be required.
  • Cabazitaxel Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy.
  • Calcium Calcium may decrease the absorption of indinavir.
  • Carbamazepine Indinavir increases the effect and toxicity of carbamazepine
  • Chlordiazepoxide The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, chlordiazepoxide.
  • Cisapride Increased risk of cardiotoxicity and arrhythmias
  • Clarithromycin Indinavir may decrease the effectiveness of clarithromycin by decreasing the formatin of the active metabolite, 14-hydroxy-clarithromycin. Clarithromycin may increase the serum concentration of indinavir. Indinavir may increase the serum concentration of clarithromycin. Consider alternate therapy or monitor the efficacy and adverse effects of both agents more closely during concomitant therapy.
  • Clonazepam The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, clonazepam.
  • Clorazepate The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, clorazepate.
  • Cyclosporine The protease inhibitor, indinavir, may increase the effect of cyclosporine.
  • Dantrolene Indinavir may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if indinavir is initiated, discontinued or dose changed.
  • Delavirdine Delavirdine may increase the effect of indinavir.
  • Diazepam The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, diazepam.
  • Dicoumarol The protease inhibitor, indinavir, may increase the anticoagulant effect of dicumarol.
  • Dihydroergotamine Indinavir may increase the serum concentration of dihydroergotamine. Concomitant therapy is contraindicated.
  • Efavirenz Efavirenz decreases the effect of indinavir
  • Ergotamine Indinavir may increase the serum concentration of ergotamine. Concomitant therapy is contraindicated.
  • Erlotinib This CYP3A4 inhibitor increases levels/toxicity of erlotinib
  • Esomeprazole Omeprazole decreases the absorption of indinavir
  • Estazolam The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, estazolam.
  • Fentanyl The protease inhibitor, indinavir, may increase the effect and toxicity of fentanyl.
  • Flurazepam The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, flurazepam.
  • Fusidic Acid Indinavir may increase the effect and toxicity of fusidic acid.
  • Halazepam The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, halazepam.
  • Ketoconazole Indinavir may increase the serum concentration of ketoconazole. Ketoconazole may increase the serum concentration of indinavir. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if either agent is initiated, discontinued or dose changed.
  • Lansoprazole Omeprazole decreases the absorption of indinavir
  • Lovastatin Indinavir may increase the effect and toxicity of lovastatin. Concomitant therapy is contraindicated.
  • Lurasidone Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated.
  • Magnesium Magnesium may decrease the absorption of indinavir.
  • Magnesium oxide The antacid decreases the absorption of indinavir
  • Midazolam The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, midazolam.
  • Omeprazole Omeprazole decreases the absorption of indinavir
  • Pantoprazole Omeprazole decreases the absorption of indinavir
  • Pimozide The protease inhibitor, indinavir, may increase the effect and toxicity of pimozide.
  • Ponatinib Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely.
  • Prazepam The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, prazepam.
  • Quazepam The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, quazepam.
  • Quinupristin This combination presents an increased risk of toxicity
  • Rabeprazole Omeprazole decreases the absorption of indinavir
  • Ranolazine Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of ranolazine by decreasing its metabolism. Concomitant therapy is contraindicated.
  • Rifabutin Rifabutin decreases the effect of indinavir
  • Rifampicin Rifampin decreases the effect of indinavir
  • Risperidone Increased risk of extrapyramidal symptoms
  • Saquinavir Possible antagonism of action
  • Saxagliptin Indinavir is an inhibitor of CYP3A4 which increases exposure of saxagliptin. Decrease dose of saxagliptin to 2.5 mg per day.
  • Sildenafil The protease inhibitor, indinavir, may increase the effect and toxicity of sildenafil.
  • Silodosin Indinavir is a strong inhibitor of CYP3A4 may increase the serum concentration of silodosin by decreasing its metabolism thus increases the potential for adverse side effects. Combination therapy is contraindicated.
  • St. John's Wort St. John's Wort decreases the effect of indinavir
  • Sunitinib Possible increase in sunitinib levels
  • Tacrolimus The protease inhibitor, Indinavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Indinavir therapy is initiated, discontinued or altered.
  • Tadalafil Indinavir may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
  • Tamoxifen Indinavir may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen.
  • Tamsulosin Indinavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Indinavir is initiated, discontinued, or dose changed.
  • Telithromycin Indinavir may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.
  • Temsirolimus Indinavir may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
  • Teniposide The strong CYP3A4 inhibitor, Indinavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Indinavir is initiated, discontinued or dose changed.
  • Terfenadine Increased risk of cardiotoxicity and arrhythmias
  • Tiagabine The strong CYP3A4 inhibitor, Indinavir, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Indinavir is initiated, discontinued or dose changed.
  • Tolterodine Indinavir may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
  • Tramadol Indinavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
  • Trazodone The protease inhibitor, Indinavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism via CYP3A4. Monitor for changes in Trazodone efficacy/toxicity if Indinavir is initiated, discontinued or dose changed.
  • Triazolam The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, triazolam.
  • Trimipramine The strong CYP3A4 inhibitor, Indinavir, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Indinavir is initiated, discontinued or dose changed.
  • Vardenafil Indinavir, a potent CYP3A4 inhibitor, may decrease the metabolism and clearance of Vardenafil. Concomitant therapy is contraindicated.
  • Vemurafenib Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely.
  • Venlafaxine Indinavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Indinavir is initiated, discontinued, or dose changed.
  • Verapamil Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Indinavir is initiated, discontinued or dose changed.
  • Vinblastine Indinavir, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Indinavir is initiated, discontinued or dose changed.
  • Vincristine Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Indinavir is initiated, discontinued or dose changed.
  • Vinorelbine Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Indinavir is initiated, discontinued or dose changed.
  • Vitamin C Vitamin C decreases indinavir levels
  • Voriconazole Voriconazole may increase the serum concentration of indinavir by decreasing its metabolism. Indinavir may increase the serum concentration of voriconazole. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed.
  • Warfarin The protease inhibitor, indinavir, may increase the anticoagulant effect of warfarin.
  • Zolpidem Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if indinavir is initiated, discontinued or dose changed.
  • Zonisamide Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if indinavir is initiated, discontinued or dose changed.
  • Zopiclone Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if indinavir is initiated, discontinued or dose changed.
Liều Lượng & Cách Dùng : Capsule - Oral
Dữ Kiện Thương Mại
Giá thị trường
Nhà Sản Xuất
  • Công ty : Merck
    Sản phẩm biệt dược : Crixivan
... loading
... loading